Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's disease (AD) is associated with reduced insulin level and impairment of insulin receptor (IR) signaling in the brain, which correlates to amyloid pathology, neuroinflammation, and synaptic neurotoxicity.
|
27730514 |
2017 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is associated with progressive impairments in brain insulin, insulin-like growth factor (IGF), and insulin receptor substrate (IRS) signaling through Akt pathways that regulate neuronal growth, survival, metabolism, and plasticity.The intracerebral streptozotocin (i.c.
|
27802237 |
2017 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Insulin receptor pathology is an important feature of AD brains that impairs the neuroprotective actions of central insulin signaling.
|
29435980 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.
|
29512653 |
2018 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Across multiple samples (n = 4502), the biologically informed, mesocorticolimbic or hippocampal specific insulin receptor polygenic scores were calculated, and their ability to predict impulsivity, risk for addiction, cognitive performance and presence of Alzheimer's disease was investigated.
|
30922963 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Brain protein O-GlcNAcylation is diminished in Alzheimer's disease (AD), and OGT targets include proteins of the insulin-signaling pathway (e.g., insulin receptor susbtrate-1, IRS-1).
|
29154269 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Combination of Insulin with a GLP1 Agonist Is Associated with Better Memory and Normal Expression of Insulin Receptor Pathway Genes in a Mouse Model of Alzheimer's Disease.
|
30635783 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Corrigendum: Involvement of insulin receptor substrates in cognitive impairment and Alzheimer's disease.
|
31823898 |
2020 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cross-species microarray analysis with the OSCAR system suggests an INSR->Pax6->NQO1 neuro-protective pathway in aging and Alzheimer's disease.
|
17545194 |
2007 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Decreased neuronal insulin receptor (IR) signaling in Alzheimer's disease is suggested to contribute to synaptic loss and neurodegeneration.
|
27639375 |
2016 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Defective insulin receptor signalings are associated with the dementia in normal aging and patients with age-related neurodegenerative diseases (e.g., Alzheimer's disease); the cognitive impairment can be reversed with systemic administration of insulin in the euglycemic condition.
|
16210778 |
2005 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Disturbances of brain glucose uptake, glucose tolerance, glucose utilization and of the insulin/insulin receptor signaling cascade are thought to be key features of the pathophysiology of AD.
|
26268335 |
2016 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Evidence for altered insulin receptor signaling in Alzheimer's disease.
|
29353052 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Following these discoveries, evidence of decreased brain insulin receptor number and function was reported in both clinical samples and animal models of aging and Alzheimer's disease, setting the stage for the hypothesis that neuronal insulin resistance may underlie memory loss in these conditions.
|
30576640 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, postmortem analyses of brains from patients with AD revealed a markedly downregulated expression of insulin receptor (IR), IGF-1 receptor (IGF-1R), insulin receptor substrate (IRS)-1 and IRS-2, and these changes progress with severity of neurodegeneration.
|
19519303 |
2009 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we show that microRNA 7 (miR-7), an abundant microRNA in the brain, targets insulin receptor (INSR), insulin receptor substrate 2 (IRS-2), and insulin-degrading enzyme (IDE), key regulators of insulin homeostatic functions in the central nervous system (CNS) and the pathology of AD.
|
31501273 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
However, when the samples were analyzed separately according to the region of the brain, there was a significant upregulation of INSR expression in the hippocampus and the entorhinal cortex in the AD patient group.
|
28164769 |
2017 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this regard, it is of note that upregulation of plasma adiponectin (APN), a benign adipokine that sensitizes the insulin receptor signaling pathway and suppresses inflammation, has recently been associated with the severities of amyloid deposits and cognitive deficits in the elderly, suggesting that APN may enhance the risk of AD.
|
28812049 |
2017 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Insulin and the IR are also present in the brain, and since there is evidence that neuronal insulin signaling regulates synaptic plasticity and that it is impaired in disease, this pathway might be the key to protection or reversal of symptoms, especially in Alzheimer's disease.
|
27889917 |
2017 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
RGD |
Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease.
|
16627931 |
2006 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Involvement of insulin receptor substrates in cognitive impairment and Alzheimer's disease.
|
30964050 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
CTD_human |
Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
|
24055495 |
2014 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that the difference in IR binding and effect on protein expression downstream of the IR may affect onset and progression of AD.
|
29450841 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimer's disease and normalized by treatment with anti-diabetic agents.
|
30383799 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease?
|
28470423 |
2017 |